PARACHUTE China Approval Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02240940|
Recruitment Status : Terminated (Company closed)
First Posted : September 16, 2014
Last Update Posted : June 22, 2017
|Condition or disease||Intervention/treatment|
|Ischemic Heart Failure||Device: Parachute Implant|
CardioKinetix has developed a catheter-based treatment method that can be used for treating patients with heart failure due to ischemic heart disease (left ventricle enlargement after anterior wall myocardial infarction). This implant device, called the "Parachute," is a partitioning membrane placed inside the apex of an enlarged ventricle with motion abnormalities. The Parachute implant device can then isolate the dysfunctional apex region in the ventricle, reduce ventricular volume, and improve left ventricular diastolic compliance.
Patients approved for enrollment after screening by cardiac CT or MRI will be implanted with a Parachute implant device (the study device). Patients will receive all appropriate medical therapy (AAMT) approved by their physician.
The patient cohort will include patients with heart failure who have wall motion abnormalities due to previous myocardial infarction, left ventricular ejection fraction ≤40% and ≥15%, and NYHA class II - IV（non-hospitalized). A maximum of 30 patients will be enrolled at seven centers. Patients who have passed screening with transthoracic echocardiography (TTE) and cardiac CT or MRI will be enrolled in the trial.
After confirming that a patient meets the enrollment qualifications with cardiac CT or MRI evaluation, the patient will be enrolled in the trial and will be implanted with a Parachute device and treated with warfarin/aspirin anticoagulation therapy.
In the follow-up periods 3 months, 6 months, and 1 year after surgery, clinical evaluation, TTE testing, functional assessment, 6-minute walk test, and evaluation of adverse events will be done.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||PARACHUTE China: Multi-center, Prospective, Single-arm Clinical Evaluation of the Safety and Efficacy of the Parachute Percutaneous Left Ventricle Partitioning System|
|Study Start Date :||September 2014|
|Primary Completion Date :||May 2015|
|Study Completion Date :||June 2017|
Experimental: Parachute Implant
Appropriate patients meeting inclusion / exclusion will be implanted with the Parachute device after screening with transthoracic echocardiography (TTE) and cardiac CT or MRI.
Device: Parachute Implant
CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
- Reduction of LVESVi [ Time Frame: 3 months ]The primary outcome measure is comparison of reduction in left ventricle end systolic volume index（LVESVi) after 3 months with baseline LVESVi. Evaluation will be performed via transthoracic echocardiography (TTE) by an independent central ultrasound laboratory (Yale University Clinical Research).
- Major Adverse Cardiac Events [ Time Frame: 3 months ]Major adverse cardiac events (MACE) are defined as death from any cause, myocardial infarction, need for elective or urgent cardiac or thoracic aortic surgery or need for use of device or device surgery with a catheter as the basis of interventional therapy, or total renal failure requiring dialysis. The Kaplan-Meier method will be used to evaluate event-free survival after Parachute implantation.
- Improvement in NYHA Class [ Time Frame: 3 months ]All patients will undergo NYHA class evaluation at each time point. At the 3-month follow-up visit, the percentage of patients who have improvement in NYHA class (an improvement of at least 1 in comparison with NYHA class at baseline) will be measured.
- Improvement in 6 minute walk test [ Time Frame: 3 months ]The difference in the distance of the 6-minute walk will be measured by comparing the distance walked at the 3-month follow-up visit with the baseline distance walked.
- Improvement in Quality of Life [ Time Frame: 3 months ]The difference in EQ5D score by comparing EQ5D score at the 3-month follow-up visit with the EQ5D score at baseline will be measured.
- Procedural Success [ Time Frame: Day 0 ]
Technical success: Success in releasing the Parachute implant or successful completion of surgery.
Combined success：The release of all devices with no serious adverse events, additional intervention surgeries, embolisms, technical failures (displacement, loss, etc.) or other problems.
- Long-term Safety [ Time Frame: 6 months and 1 year ]
Patients will be invited to continue participating in an extended observation study at 6 and 12 months. Patients who agree to participate 6 months and 12 months after surgery will receive the same evaluations as described in the 3-month follow-up visit.
Descriptive reports of safety will be made using all the information gathered through the core research and the additional information from the extended observation period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02240940
|Chinese Academy of Medical Sciences Fu Wai Hospital|
|Beijing, Beijing, China|
|Peking University First Hospital|
|Beijing, Beijing, China|
|Second Affiliated Hospital of Zhejiang University Medical College|
|Hangzhou, Zhejiang, China, 310016|
|10th People's Hospital Affiliated to Tongji University|
|Shanghai Jiaotong University School of Medicine Ruijin Hospital|
|Zhongshang Hospital of Fudan University|
|General Hospital of Shenyang Military Region|
|Shenyang City, China|
|Study Chair:||Runlin Gao, MD||Chinese Academy of Medical Sciences, Fu Wai Hospital|
|Principal Investigator:||Yuejin Yang, MD||Chinese Academy of Medical Sciences, Fu Wai Hospital|
|Principal Investigator:||Yuong Huo, MD||Peking University First Hospital|